
OSTX
Healthcare · Biotechnology · $34.9M market cap
$0.7450-0.01 (-0.7%)Nov 13, 4:24 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +39.0% over 90 days · 30-day revisions 3 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | Time not confirmed | -0.13 | — | — |
| Aug 14, 2026 | After the close | -0.25 | -0.20 | +20.0% |
| May 18, 2026 | Before the open | -0.19 | -0.27 | -42.1% |
| Nov 14, 2025 | After the close | -0.12 | -0.21 | -75.0% |
| Aug 18, 2025 | After the close | -0.15 | -0.19 | -26.7% |
| May 15, 2025 | After the close | -0.11 | -0.18 | -63.6% |
| Mar 31, 2025 | Time not confirmed | -0.14 | -0.19 | -35.7% |
| Nov 15, 2024 | Before the open | -0.08 | -0.18 | -125.0% |
| Aug 28, 2024 | Time not confirmed | — | -0.61 | — |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker…